⌘K
Loading ticker…
As of 2026-08-24, Immuneering Corporation Class A Common Stock (IMRX) has a 3-month relative strength percentile of 40 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 47. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.1%, relative volume 0.61×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY diluted average shares. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
IMRX appears in 1 ETF as of May 2026: AVSC at 0.01% weight, $302K notional.
Held by 1 ETFs · $302K across latest filings · largest weight 0.01% (AVSC).
Top 1 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| AVSC | 0.01% | $302K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | IMRX Jan avg: -18.80% median: -16.87% win: 0% σ: 8.06% n: 4 2022-04-12 → 2026-07-31 | IMRX Feb avg: 3.79% median: 6.70% win: 75% σ: 13.38% n: 4 2022-04-12 → 2026-07-31 | IMRX Mar avg: 10.73% median: -1.13% win: 50% σ: 63.77% n: 4 2022-04-12 → 2026-07-31 | IMRX Apr avg: -17.57% median: -21.71% win: 20% σ: 24.79% n: 5 2022-04-12 → 2026-07-31 | IMRX May avg: 2.48% median: -2.11% win: 40% σ: 27.15% n: 5 2022-04-12 → 2026-07-31 | IMRX Jun avg: 25.45% median: 20.76% win: 60% σ: 44.20% n: 5 2022-04-12 → 2026-07-31 | IMRX Jul avg: -1.23% median: 0.20% win: 60% σ: 14.59% n: 5 2022-04-12 → 2026-07-31 | IMRX Aug avg: 9.91% median: -6.54% win: 25% σ: 38.54% n: 4 2022-04-12 → 2026-07-31 (current) | IMRX Sep avg: 71.98% median: 73.03% win: 75% σ: 81.56% n: 4 2022-04-12 → 2026-07-31 | IMRX Oct avg: -9.73% median: -5.87% win: 0% σ: 10.76% n: 4 2022-04-12 → 2026-07-31 | IMRX Nov avg: -8.99% median: 2.41% win: 50% σ: 30.72% n: 4 2022-04-12 → 2026-07-31 | IMRX Dec avg: -5.52% median: -4.42% win: 50% σ: 17.21% n: 4 2022-04-12 → 2026-07-31 |